At least half of women experience urinary incontinence at some point in their lives but few discuss the condition with their physicians. In part, that’s because most women believe few effective treatments exist for urinary leakage – and until recently, they were right. Several advances in 2024, however, offer new hope.

Women with endometriosis may soon be able to have a simple blood test to diagnose their disease thanks to a breakthrough by Proteomics International Ltd. that has developed a plasma protein biomarker panel that identifies all stages of endometriosis.

Celmatix Therapeutics (Celmatix Inc.) has announced a new drug program for endometriosis, with the development of a novel Jun-N-terminal kinase (JNK) inhibitor that targets pain and inflammation. The company’s aim to focus on JNK inhibitors with greater specificity for JNK1 and JNK3 than for JNK2 led it to license lead compounds from Baylor College of Medicine.